GANTRISIN PEDIATRIC
LOE ApproachingNDAORALSUSPENSION
Approved
Dec 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTRISIN PEDIATRIC is an oral suspension antibiotic approved in 1953 for pediatric patients. The product represents a legacy small-molecule antimicrobial with a well-established safety profile in children. Generic equivalents and newer antimicrobial classes have significantly eroded its market position since approval.
LOE Approaching
With LOE approaching and minimal linked job activity, this product likely operates as a legacy brand with a small, maintenance-focused commercial team managing decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect this product's status as a legacy brand with no active growth initiatives. Roles supporting GANTRISIN PEDIATRIC involve compliance, supply-chain management, and stewardship of an aging portfolio asset rather than innovation or expansion.
Brand ManagerRegulatory Affairs Specialist
Worked on GANTRISIN PEDIATRIC at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.